 |
 |
 |
 |
 |
 |
||
 |
 |
 |
 |
 |
| 查看: 9505 | 回復(fù): 17 | ||
shekai新蟲 (初入文壇)
|
[求助]
關(guān)于HSV-2生殖器皰疹病毒的研究進(jìn)展與攻克期待。 已有2人參與
|
|
有數(shù)據(jù)顯示美國人有近6000萬（近人口總數(shù)20%）感染了HSV-2生殖器皰疹病毒，該病很容易復(fù)發(fā)，是性傳播疾病一種，而且，聽說HSV-2和HSV-1兩種病毒比艾滋和肝炎病毒等都要簡(jiǎn)單點(diǎn)，HSV-2在人體不能得到根本清除是由于部分影藏在神經(jīng)細(xì)胞中，而類似于阿昔洛韋這類藥物不能進(jìn)入這類細(xì)胞，只能在發(fā)病時(shí)候，進(jìn)行治療。 這是一個(gè)很大的市場(chǎng)，聽說美國在研究根治的方面投入較大。 我本人是學(xué)工科的，但知道今后幾十年，在基因和納米領(lǐng)域，科技很可能會(huì)有突破技術(shù)發(fā)生。 我想請(qǐng)問各位研究病毒學(xué)的同學(xué)，就您們的了解，人類攻破該類病毒，得到徹底治愈的藥物還會(huì)要多長(zhǎng)時(shí)間列？ 非常謝謝！期待您們的回復(fù)。 [ Last edited by silicare on 2014-2-18 at 09:00 ] |
回復(fù)此樓» 猜你喜歡
311求調(diào)劑
已經(jīng)有9人回復(fù)
-
302求調(diào)劑
已經(jīng)有4人回復(fù)
-
被我言中：新模板不強(qiáng)調(diào)格式了，假專家開始管格式了
已經(jīng)有4人回復(fù)
-
303求調(diào)劑
已經(jīng)有5人回復(fù)
-
考研求調(diào)劑
已經(jīng)有4人回復(fù)
-
085601專碩，總分342求調(diào)劑，地區(qū)不限
已經(jīng)有4人回復(fù)
-
085601材料工程專碩求調(diào)劑
已經(jīng)有5人回復(fù)
-
一志愿天津大學(xué)化學(xué)工藝專業(yè)（081702）315分求調(diào)劑
已經(jīng)有6人回復(fù)
-
能源材料化學(xué)課題組招收碩士研究生8-10名
已經(jīng)有6人回復(fù)
-
296求調(diào)劑
已經(jīng)有5人回復(fù)
» 本主題相關(guān)商家推薦: (我也要在這里推廣)
» 本主題相關(guān)價(jià)值貼推薦，對(duì)您同樣有幫助:
- 丙炔酸做成酰氯的問題，期待各位大俠相助！��！
已經(jīng)有11人回復(fù)
- 鐵基超導(dǎo)體研究獲進(jìn)展
已經(jīng)有5人回復(fù)
- 病毒免疫學(xué)——一塊自己很渴望研究的領(lǐng)域
已經(jīng)有6人回復(fù)
- 請(qǐng)問HSV-2生殖器皰疹病毒根治藥物研究突破預(yù)測(cè)下。
已經(jīng)有6人回復(fù)
- 【轉(zhuǎn)帖】生殖器皰疹疫苗臨床試驗(yàn)失敗
已經(jīng)有8人回復(fù)
- 【原創(chuàng)】撒金幣求洪堡推薦信模版，期待達(dá)人�。�！
已經(jīng)有3人回復(fù)
- 【其他】環(huán)境化學(xué)與生態(tài)毒理學(xué)課題組期待生物專業(yè)（熟悉魚的毒理學(xué)研究）人員加入
已經(jīng)有5人回復(fù)
- 【求助】求助：孕婦早期得帶狀皰疹怎么辦？
已經(jīng)有7人回復(fù)
- 【交流】山東農(nóng)藥淡市布局 期待旺市
已經(jīng)有3人回復(fù)
- 【其它】金標(biāo)納米粒子應(yīng)用于生物芯片研究進(jìn)展
已經(jīng)有4人回復(fù)
shekai
新蟲 (初入文壇)
- 應(yīng)助: 0 (幼兒園)
- 金幣: 8
- 帖子: 7
- 在線: 1.9小時(shí)
- 蟲號(hào): 84200
- 注冊(cè): 2005-08-03
- 性別: GG
- 專業(yè): 通信理論與系統(tǒng)
2樓2011-08-26 20:10:35
3樓2011-08-27 08:36:11
shekai
新蟲 (初入文壇)
- 應(yīng)助: 0 (幼兒園)
- 金幣: 8
- 帖子: 7
- 在線: 1.9小時(shí)
- 蟲號(hào): 84200
- 注冊(cè): 2005-08-03
- 性別: GG
- 專業(yè): 通信理論與系統(tǒng)
4樓2011-08-27 16:28:16
| 頂一下。 |
5樓2011-08-28 15:30:02
|
本帖內(nèi)容被屏蔽 |
6樓2011-08-28 15:53:19
kevintz
木蟲 (正式寫手)
- 應(yīng)助: 0 (幼兒園)
- 金幣: 1773.7
- 散金: 5
- 紅花: 2
- 帖子: 559
- 在線: 604.2小時(shí)
- 蟲號(hào): 157550
- 注冊(cè): 2006-01-06
- 性別: GG
- 專業(yè): 病毒、病毒感染與宿主免疫
【答案】應(yīng)助回帖
|
皰疹病毒很多種類，HSV-1,-2, VSV等等，人類很小時(shí)候就會(huì)感染一種或幾種，之后病毒潛伏在神經(jīng)細(xì)胞中，在身體抵抗力下降時(shí)，重新復(fù)發(fā)。 潛伏在神經(jīng)細(xì)胞中的病毒基因不表達(dá)或不完全表達(dá)，人體免疫系統(tǒng)和藥物都不能將其殺滅。研究策略現(xiàn)在一般有如下思路：1）誘導(dǎo)潛伏的病毒復(fù)發(fā)，后藥物治療；2）阻斷病毒潛伏相關(guān)的基因或蛋白。有些研究進(jìn)展，但20-30年內(nèi)很難有效根除。 |
7樓2011-08-28 20:47:56
8樓2011-08-28 21:43:35
9樓2011-08-30 19:28:09
|
轉(zhuǎn)個(gè)我看到的國外消息： “Earlier this year I discussed Vical (VICL), one of those biotechnology companies that appear to be flying under almost everyone's radar. The corporation, based in San Diego, CA, has, for a young biotech company, a deep pipeline as well as two products on the market, one to protect farm-raised salmon and another to increase the survival time of dogs with oral melanoma. But what really excites me about Vical, in addition to its work on cancer immunotherapies and, specifically, its Phase III study of Allovectin®, is the company’s seminal research and development in the area of the herpes simplex virus and the development of the corporation’s herpes simplex virus type 2 or HSV-2 vaccine. 在美guo加州的這家公司就是 vical 它是一家主要致力研究治療生殖器皰疹的生化公司。（ 迷糊以前提及過這個(gè)藥而且多次提及。 ）這家公司目前主要專攻癌癥的免疫力治療還有就是已經(jīng)進(jìn)入三期實(shí)驗(yàn)的專制生殖器皰疹的藥名叫 allovectin 目前此藥已經(jīng)申請(qǐng)專利并注冊(cè)。 這是一個(gè)疫苗藥物。 Of the two serotypes identified, HSV-1 and HSV-2, the latter is most common in the United States. HSV-2 is a sexually transmitted virus which is the leading cause of genital herpes. Approximately one out of every six individuals in the United States and an estimated one out of every four worldwide is infected by HSV-2 before age 50. Even more disconcerting, perhaps, as noted by Vical at the recent BIO International Convention, 二型皰疹是性病在美guo很普遍。 每六個(gè)人中就有一個(gè)人有這個(gè)病， 世界范圍內(nèi)五十歲之前的人每四個(gè)人就有一個(gè)人有此病。 在今年召開的那次生化會(huì)議上 這家公司把這些都做了論述 “[I]n the United States, at least 40 million people are infected with HSV-2, and approximately 1.6 million people are newly infected each year, with approximately 500,000 of those suffering from disease symptoms. Even higher infection rates are evident in developing countries, with further complications in people also infected with HIV.” 在美guo四千萬人患有此病。 每一年新病人160萬人。 其中這些病人中50萬人是有疾病癥狀的。 （這說明大多數(shù)人得病沒有癥狀， 而我們這些倒霉蛋都是有癥狀的） 發(fā)展中g(shù)uo家呈現(xiàn)上升趨勢(shì)， 艾滋患者的癥狀更復(fù)雜 Importantly, there is, currently, no cure for genital herpes. It is a recurrent, lifelong viral infection. But under a grant from the National Institute of Allergy and Infectious Diseases Division of the National Institutes of Health ((NIH)), the effort mounted by Vical is directed at developing a plasmid DNA-based vaccine to inhibit recurring lesions in patients latently infected with HSV-2. And while still in the preclinical stage, results have shown a reproducible statistically significant reduction in viral lesion occurrence in guinea pigs latently infected with HSV-2. 此病無法治愈。 是終生的病毒感染 （真難過） 但是在guo家健康部門的授權(quán)下， 這家公司正致力研究對(duì)付二型皰疹的基因基礎(chǔ)的疫苗來對(duì)付皰疹的復(fù)發(fā)。 雖然還沒有人體試驗(yàn)， 但是在豬身上的試驗(yàn)已經(jīng)成功， 能夠抑制復(fù)發(fā) Development of the HSV-2 vaccine is being done in collaboration with the University Of Washington School Of Medicine and the Sealy Center for Vaccine Development at the University of Texas Medical Branch under the NIH grant cited above. The initial focus will be for people already infected with HSV-2, with the goal of reducing or eliminating periodic viral flare-ups as well as viral shedding and transmission. 這項(xiàng)試驗(yàn)是與華盛頓大學(xué)和德克薩斯大學(xué)一起聯(lián)合進(jìn)行的。 是針對(duì)已經(jīng)感染生殖器皰疹病人的。 抑制復(fù)發(fā)， 防治傳染已經(jīng)減輕癥狀。 還有消滅病毒的活躍 What had researchers and medical practitioners excited at this year’s BIO International Convention were data presented by Vical that showed its therapeutic vaccine “…significantly reduced the recurrence of HSV-2 lesions in guinea pigs with latent infection (p<0.05).” Vical also presented data for a related prophylactic vaccine that demonstrated how this version “…protected mice against lethal HSV-2 challenge (p<0.0001), provided sterilizing immunity(p<0.05) and inhibited post-challenge viral shedding at the primary infection site (p<0.05) and viral load at the latent infection site (p=0.007).” 在今年的世界生化大會(huì)上， 這家公司公布了在豬身上實(shí)驗(yàn)的所有數(shù)據(jù)。 以及在耗子身上的試驗(yàn)結(jié)果。 數(shù)據(jù)顯示徹底被抑制。 What some consider even more exciting were the results announced a month later at the DNA Vaccines 2011 Conference. According to Sean M. Sullivan, Ph.D., Vical's Executive Director of Pharmaceutical Sciences, 八月的大會(huì)這家公司的老板又宣布了好消息。 用了這個(gè)疫苗根本不會(huì)復(fù)發(fā)， 在豬身上顯示成功 “[A] Vaxfectin®-formulated trivalent therapeutic version of the vaccine … significantly reduced (p<0.05) the recurrence of lesions in guinea pigs with latent infection as well as viral shedding.” In addition “… a 0.1 µg dose of the prophylactic vaccine provided 100% protection of mice against challenge with 50 times a lethal dose, and a 100 µg dose of the prophylactic vaccine provided 100% protection of mice against challenge with 500 times a lethal dose. The 100 µg dose of the prophylactic vaccine also significantly reduced viral shedding at the primary infection site (p<0.001) and inhibited viral counts at the latent infection site (pd0.05). Both the monovalent and trivalent vaccines completely eliminated primary disease and recurrent disease in a prophylactic guinea pig model.” To say these results are significant is understatement. However, whether or not Vical can achieve equally compelling results in the clinic with human subjects obviously is the key question, and one for which both the medical and financial communities await an answer. After all, according to Vical, estimated direct costs of treating HSV-2 in the United States alone are close to $1 billion annually, primarily for drugs and outpatient medical care, plus additional indirect costs of more than $200 million. If the company is successful in developing an FDA-approved HSV-2 vaccine formulated with its Vaxfectin® adjuvant, the revenues in the US alone would push VICL into biotech’s major leagues. 豬身上成功了不能說明問題， 人身上成功才是關(guān)鍵。 每一年在美guo在二型皰疹上的病人買藥消費(fèi)達(dá)到十億美金。 還有近兩億美金的間接消費(fèi)。 如果這家公司成功把此藥推向市場(chǎng) 那光是美guo的營業(yè)額就是一個(gè)天文數(shù)字了吧。 （如果哪家公司在這各方面成功那將是創(chuàng)造神話， 不光是印鈔機(jī)了） ” 我的問題是，人體試驗(yàn)成功可能性是不是仍然很小列？ 對(duì)于藥物研發(fā)，是不是大多數(shù)是在人體試驗(yàn)階段失敗的�。� 謝謝！ |
10樓2011-08-31 15:23:42
相關(guān)版塊跳轉(zhuǎn)
我要訂閱樓主 shekai 的主題更新
| 最具人氣熱帖推薦 [查看全部] | 作者 | 回/看 | 最后發(fā)表 | |
|---|---|---|---|---|
|
[考研] 312求調(diào)劑 +4 | 陌宸希 2026-03-16 | 5/250 |
|
|---|---|---|---|---|
|
[考研] 工科材料085601 279求調(diào)劑 +3 | 困于星晨 2026-03-17 | 3/150 |
|
|
|
[考博] 26申博 +4 | 八旬速覽 2026-03-16 | 4/200 |
|
|
|
[碩博家園] 深圳大學(xué)碩士招生（2026秋，傳感器方向，僅錄取第一志愿） +4 | xujiaoszu 2026-03-11 | 9/450 |
|
|
|
[考研] 289求調(diào)劑 +6 | 步川酷紫123 2026-03-11 | 6/300 |
|
|
|
[考研] 化學(xué)調(diào)劑0703 +8 | 啊我我的 2026-03-11 | 8/400 |
|
|
|
[考研] 一志愿985，本科211，0817化學(xué)工程與技術(shù)319求調(diào)劑 +5 | Liwangman 2026-03-15 | 5/250 |
|
|
|
[考研] 321求調(diào)劑 +5 | 大米飯！ 2026-03-15 | 5/250 |
|
|
|
[考研] 0703 物理化學(xué)調(diào)劑 +3 | 我可以上岸的對(duì)?/a> 2026-03-13 | 5/250 |
|
|
|
[考研] 求老師收留調(diào)劑 +4 | jiang姜66 2026-03-14 | 5/250 |
|
|
|
[考研]
 機(jī)械專碩調(diào)劑
+3
|
笨笨兔子 2026-03-12 | 3/150 |
|
|
|
[考研] 中科大材料與化工319求調(diào)劑 +3 | 孟鑫材料 2026-03-14 | 3/150 |
|
|
|
[考研] 308求調(diào)劑 +5 | 是Lupa啊 2026-03-11 | 5/250 |
|
|
|
[考研] 求材料調(diào)劑 085600英一數(shù)二總分302 前三科235 精通機(jī)器學(xué)習(xí) 一志愿哈工大 +4 | 林yaxin 2026-03-12 | 4/200 |
|
|
|
[考研] 290求調(diào)劑 +9 | ADT 2026-03-11 | 9/450 |
|
|
|
[考研] 工科，求調(diào)劑 +3 | 我887 2026-03-11 | 3/150 |
|
|
|
[考研] 281求調(diào)劑 +9 | Koxui 2026-03-12 | 11/550 |
|
|
|
[考研] 工科材料085601 279求調(diào)劑 +8 | 困于星晨 2026-03-12 | 10/500 |
|
|
|
[考研] 一志愿211化學(xué)學(xué)碩310分求調(diào)劑 +8 | 努力奮斗112 2026-03-12 | 9/450 |
|
|
|
[考博] 福州大學(xué)楊黃浩課題組招收2026年專業(yè)學(xué)位博士研究生，2026.03.20截止 +3 | Xiangyu_ou 2026-03-12 | 3/150 |
|